Valuation: Wockhardt Limited

Market Cap 339B 3.53B 3.08B 2.91B 2.64B 4.95B 4.97B 34.84B 13.45B 172B 13.27B 12.98B 555B P/E 2025
-472x
P/E 2026 89.7x
Enterprise Value 355B 3.69B 3.22B 3.04B 2.76B 5.18B 5.2B 36.44B 14.06B 180B 13.88B 13.57B 580B EV / Sales 2025
8.1x
EV / Sales 2026 5.97x
Free-Float
48.98%
Yield 2025 *
-
Yield 2026 -
1 day+0.67%
1 week-4.28%
Current month+10.74%
1 month+12.16%
3 months+4.87%
6 months+71.61%
Current year+44.25%
1 week 1,967.3
Extreme 1967.3
2,193.8
1 month 1,825
Extreme 1825
2,272.9
Current year 1,086.7
Extreme 1086.7
2,422.3
1 year 1,086.7
Extreme 1086.7
2,422.3
3 years 213.25
Extreme 213.25
2,422.3
5 years 145.15
Extreme 145.15
2,422.3
10 years 145.15
Extreme 145.15
2,422.3
Manager TitleAgeSince
Chief Executive Officer 53 2009-03-31
Director of Finance/CFO - 2022-02-28
Chief Tech/Sci/R&D Officer - 1998-04-30
Director TitleAgeSince
Chairman 83 2009-11-05
Director/Board Member 53 2009-11-05
Director/Board Member 55 1996-06-30
Change 5-day change 1-year change 3-year change Capi.($)
+0.67%-4.28%+36.66%+761.49% 3.52B
-1.61%-0.15%+11.45%+60.09% 46.78B
-1.02%-1.90%+35.99%+100.50% 37.88B
+2.19%+3.65%+10.70%+80.29% 11.82B
+1.32%+2.09%-11.64%+12.41% 11.61B
-0.95%0.00%+18.72%+150.00% 9.12B
+0.39%+2.39%+29.99%+38.63% 7.38B
-0.06%+2.97%+38.90%-18.67% 7.21B
+1.30%+1.17%+16.08%+187.41% 7.12B
+0.70%+1.10%-44.22%+5.78% 4.99B
Average +0.29%-0.27%+14.26%+137.79% 14.74B
Weighted average by Cap. -0.43%-0.25%+17.54%+90.02%

Financials

2025 2026
Net sales 30.35B 316M 276M 260M 236M 443M 445M 3.12B 1.2B 15.43B 1.19B 1.16B 49.65B 34.62B 361M 315M 297M 270M 505M 508M 3.56B 1.37B 17.6B 1.36B 1.33B 56.63B
Net income -470M -4.9M -4.27M -4.03M -3.66M -6.86M -6.89M -48.31M -18.64M -239M -18.4M -17.99M -769M 2.13B 22.2M 19.36M 18.28M 16.6M 31.1M 31.23M 219M 84.49M 1.08B 83.39M 81.54M 3.48B
Net Debt 14.33B 149M 130M 123M 112M 209M 210M 1.47B 568M 7.29B 561M 549M 23.44B 15.53B 162M 141M 133M 121M 227M 228M 1.6B 616M 7.9B 608M 594M 25.41B
Logo Wockhardt Limited
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
Employees
2,564
Date Price Change Volume
26-09-18 ₹2,086.10 +0.67% 557,349
26-09-17 ₹2,072.30 +2.51% 603,193
26-09-16 ₹2,021.50 -2.06% 1,262,973
26-09-15 ₹2,064.10 -5.29% 851,928
26-09-11 ₹2,179.40 -1.86% 1,109,909
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. WOCKPHARMA Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!